Got 2 minutes to spare? Then sit back and enjoy a mix of fact, fantasy & tongue-n-cheek from “yours truly” (Dr. Anthony G. Payne)
Many know me as “Anthony the writer”. Many doctors and clinics and labs know me as “Anthony the theorist”. Actually a more apt moniker might be “Anthony the behind the scenes guy” as so much of my work is on behalf of companies and individual docs who pay to get my ideas and handiwork and affix their name to it without any mention of my authorship. All this ghostwriting, ghost-editing and ghost-theorizing has helped carve out a niche for me as, well,…a living, breathing ghost (The working world’s invisible man).
However, some of the ventures and projects I am involved with can now be divulged albeit sans key details that could be ripped off and exploited by corporate competition aka money grubbing predators and scavengers.
Amyotrophic Lateral Sclerosis (ALS): Like cancer ALS is a hellacious nut to crack on all kinds of levels. However, evidence has emerged that suggests the disease is influence by aberrant proteins called prions and disease progress reflects the spread of these prions in the central nervous system (CNS). As part of my consultancy work for Nova Cells Institute of Mexico I crafted an experimental combination drug and nondrug anti-prion regimen which was entrusted to NCIM’s affiliated MDs (which they then approved and began using). This plus NCIM’s proprietary primed stem cells and unique cytokine-protein intravenous product dubbed “Beacon Factor” has, since 2009, slowed progression to a crawl in many treated ALS patients and has so far spared all of those treated from compromised respiratory functioning. Of the handful who have died all of them simply went to sleep one night and didn’t wake up (“A good death” in many people’s book).
One ALS patient’s neurology team at Duke University commented that “Whatever these Nova Cells people have come up with seems to be working. They know their business”.
Atherosclerosis (Arterial blockage): The challenge of reversing arterial blockage has intrigued and engaged me since the mid-1980s. In fact, back then I was working with a Tibetan herbal formula called PADMA 28 that had accumulated evidence (from lab studies and also randomized clinical trials) that it significantly reduced players in the arterial plaque-building process. I was, in fact, so impressed by the science that I approached the company that had brought PADMA 28 into the USA from Switzerland (where it is Swiss FDA approved to treated intermittent claudication), Berkley Health Network (BHN – later sold and reborn as Pacific BioLogic, Inc.), and began sharing ideas concerning other applications and experimental uses. It didn’t take long before their principle technical people asked me to serve as a scientific advisor which I did. Later I did experiments in which I took a large group of guinea pigs and divided them into 2 groups: Both ate a high saturated & trans fat rich diet geared to produce artery clogging diet which resulted in significant arterial blockage. However, one also was given PADMA 28 in their chow which eventually reversed their blockage. It did this, I think, because it dropped serum lipids and triglycerides so low that their bodies began mobilizing fats and such from their arterial plague. It also countered arterial and systemic inflammation which is a player in the plaque-building process.
In the years since I have added dietary and other measures to the PADMA 28 (now marketed as PADMA BASIC®) to increase plague reversal. Since I am not a physician and cannot diagnose or prescribe treatments, I have entrusted my ever-evolving ideas & resulting regimens to licensed MDs and DOs for their discretionary use. What has emerged is simply this: Many cases have accrued in which people with significant arterial blockage have demonstrated reversal to the point whereby angina and other symptoms ceased.
Note bene: I have no commercial interest in PADMA in any of its incarnations nor in any firm or such that markets or sells it.
Cancer especially advanced metastatic malignancy: Back in 1999 Wake Forest University researcher Zheng Cui, MD, PhD showed that there are super cancer-fighting immune cells called granulocytes in young animals that could obliterate cancer in old ones (mice). Borrowing a page from Dr. Cui’s animal work I created a regimen in which I proposed that pooled granulocytes isolated from the blood of young folks would be given daily to advanced cancer patients over a 10 to 14 day period (But given only to those who have exhausted conventional cancer fighting treatments and whose cancer is spreading and is predicted to end their lives in short order).
This approach was entrusted to a group of Mexican hematologists including one of the leading ones in all of Mexico and was approved for experimental clinical use (with the number of granulocytes and the frequency of their infusions to follow a strict protocol I worked out). The types of cancer subsequently treated included prostate, breast, lung, stomach and colorectal.
There is a <1% risk of a graft v. host reaction even months after a treatment cycle is concluded which all the patients doing it were informed of as part of informed consent.
To-date all advanced, end stage cancer patients treated have responded favorably with no graft v. host reactions occurring at all. Half of those treated experienced partial remission and half, full remission. Some have been technically cancer free for many, many years now.
Eczema: Back in the early 1990s J.I. Harper, MD at the Hospital for Sick Children in London, England put an ancient Chinese herbal eczema tea to the test in a double-blind placebo-controlled clinical involving children with eczema. The tea produced a tremendous diminution in itching, pustules, and scales, for example, while the children who sipped the placebo tea (the control group) did not significantly improve.
The herbs in the eczema tea were published but not the amounts of each. I decided to figure out this out carry out my own line of research. I recruited a large number of eczema patients – children, adolescents, and adults – mixed together the botanicals in varying proportions, and then gave out various versions. (Unlike the London study, however, I opted to use an encapsulated form as opposed to a foul-tasting tea).
It took over two years working at it part-time to arrive at the most effective combination for managing eczema, but effective it is! (My results paralleled those seen in the London-based clinical trials). And it’s not effective for eczema, but for other conditions in which certain species of free radicals and highly inflammatory substances called leukotrienes and prostaglandins play a role. The conditions which have shown a significant response to the eczema formula include asthma, emphysema, psoriasis, certain rheumatic conditions, and numerous neurological maladies.
I turned over the Eczema or E-Tea formula to a company I was consulting for at the time, Prestige Chinese Teas, in 1993. I’d known and collaborated with PCT founder and President Sunny Wong since 1986 and knew he’d so all he could to get E-Tea into the hands of medical consumers at a cost they could afford, which he did. I did not ask for and ever received any proceeds from the sale of E-Tea (as I did not want to add to its cost by doing so) and ceased to be paid as a consultant for PCT in 1999 when I left the USA to teach in Japan. As I anticipated, PCT has continued to make E-Tea available at a cost that is kind to consumer purse strings: http://www.teastohealth.com/skin.html
Sunny and his people have received many, many letters and statements from eczema patients, nurses and dermatologists down through the years attesting to E-Tea’s efficacy.
There are many more vexing medical challenges I have tackled down through the years (as a theorist) and a whole litany of them which has been placed on my plate by doctors, companies and even sufferers seeking answers that I am currently working on. And while I “live and move and have my being” for the most part in the Shadowlands you may come across my solutions down the line — albeit you likely will not know I am behind it.
© 2014 by Anthony G. Payne. All rights reserved.
Nota bene: Much of my work down through the years could not be published anywhere as it would compromise proprietary use by those I worked for/with.
Med Hypotheses. 2007;68(4):828-31. Epub 2006 Oct 19.
Exploiting hypoxia in solid tumors to achieve oncolysis.
Chemo- and radio-resistant cancer cells within solid tumors undermine the effectiveness of these approaches to achieving oncolysis. These resistant cells and clusters of cells typically thrive at low oxygen tensions and are reliant on anaerobic metabolic pathways that churn out lactate. This hypoxic state is one that can be exploited and in this paper a novel method is advanced involving tumor cell infiltration by bifidobacterium species which should bring about prodigious lactate synthesis; concomitant blocking of its enzymatic degradation by urea as well as export (from the cell) by use of quercetin; depletion of ATP using exogenous thyroid; and compromised oxidative catabolism of free fatty acids and amino acids via oral intake of l-hydroxycitrate, melatonin and nontoxic NDGA. This “anaerobic pathway cocktail”, it is hypothesized, will bring about a profound reduction in intracellular pH and a compromised state of cellular energetics sufficient to effect oncolysis.
Med Hypotheses. 2005;64(4):880-1.
Ciliary neurotrophic factor: its possible role as a stem cell homing beacon in neurological diseases and disorders.
Med Hypotheses. 2004;62(5):718-20.
Using immunomagnetic technology and other means to facilitate stem cell homing.
If stem cell therapy is to be maximally effective, it is vital that progenitor (stem) cells get to the target tissue(s) and/or organ(s). Three methods of facilitating stem cell homing to target tissues are explored in this paper: (1) cobalt compounds such as cobalt phthalocyanines could be magnetically delivered to target tissue(s) and/or organ(s), and then subject to a brief pulsed magnetic field or ultrasound exposure suitable to induce mild hyperthermia with the result being the synthesis of cytokines that are chemoattractants to progenitor (stem) cells; (2) ferromagnetic nanobead particles could be tagged with antibodies specific to the target tissue(s) and/or organ(s) and infused into patients, followed by introduction of progenitor (stem) cells tagged with antibody-bound magnetic nanoparticles. This should result in passive attachment (stem cells to tagged tissue or organ); and (3) Reticulose, which stimulates the synthesis of the stem cell chemoattractant IL-8, could be magnetically guided to target tissue(s) and/or organ(s).
Med Hypotheses. 2009 May;72(5):548-50. Epub 2009 Feb 5.
Experimental regimen targeting the ependyma slows disease progression in four patients with amyotrophic lateral sclerosis.
In this paper the author proposes that at least some forms of sporadic ALS (amyotrophic lateral sclerosis) arise due to the effects of neurotoxic compounds synthesized by defective ependymal cells in the brain. These cells produce cerebrospinal fluid (CSF) that is laden with neurotoxic compounds that bring about motor neuron die-off. Evidence is garnered from various animal studies to demonstrate the toxicity of CSF taken from ALS patients and by virtue of the proposed mechanism (defective ependymal cells). In addition, a regimen created by the author is introduced; a regimen that has been used by four (4) sporadic ALS patients since 2005 resulting in what appears to be a slowing of disease progression. All four patients have significantly outlived best estimates of their survival tendered by their neurologists.
Science. 2005 Jan 14;307(5707):208-9; author reply 208-9.
Inflammation and life-span.
Inflammatory exposure and historical changes in human life-spans.Finch CE, Crimmins EM. Science. 2004 Sep 17; 305(5691):1736-9.
 Anthony G. Payne*  Beneficial Effects of Subcutaneously Injected
Human Umbilical Cord Stem Cells on Cerebral Palsy and Traumatic Brain Injury in Children and a Posited Mechanism. pp. 497 – 501.
 Anthony G. Payne*  Preventing Metastasis and Achieving Oncolysis in
Solid Tumors by Inhibiting Specific Metalloproteinases and Manipulating Key
Metabolic Pathways. pp. 553-565.
 Fernando Ramirez, David A. Steenblock, Anthony G. Payne* and Lyn Darnall  Umbilical Cord Stem Cell Therapy for Cerebral Palsy. pp. 679-686.